Extended labeling issued for Euflexxa
Changes to the labeling for Euflexxa (1% sodium hyaluronate, Ferring Pharmaceuticals), a treatment for the pain associated with osteoarthritis, have been approved by the FDA.
Changes to the labeling for Euflexxa (1% sodium hyaluronate, Ferring Pharmaceuticals), a treatment for the pain associated with osteoarthritis, have been approved by the FDA. The product can now be stored at room temperature, as well as refrigerated. The new labeling will make it easier for physicians to store the drug and keep it available for patients, according to the company. The highly purified hyaluronan product is a non-avian-derived hyaluronic acid that is administered as a three-injection treatment regimen for patients who have failed to adequately respond to conservative nonpharmacologic therapy and simple analgesics.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
To go to the Drug Topics homepage, click here http://www.drugtopics.com.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
